We are live on ! Find out more
IMRX icon

Immuneering
IMRX

32 hedge funds and large institutions have $172M invested in Immuneering in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more capital invested

Capital invested by funds: $65.7M → $172M (+$107M)

0.32% less ownership

Funds ownership: 46.04% → 45.71% (-0.32%)

14% less funds holding

Funds holding: 37 → 32 (-5)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
32
Holders Change
-5
Holders Change %
-13.51%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$754K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$618K
3
BlackRock
BlackRock
New York
+$535K
4
Marshall Wace
Marshall Wace
United Kingdom
+$533K
5
GCP
GSA Capital Partners
United Kingdom
+$263K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.81M
2
SCM
Suvretta Capital Management
New York
-$1.08M
3
Millennium Management
Millennium Management
New York
-$940K
4
Renaissance Technologies
Renaissance Technologies
New York
-$138K
5
Citadel Advisors
Citadel Advisors
Florida
-$114K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$39K -$881 -111 -4%
JP Morgan Chase
27
JP Morgan Chase
New York
$16K +$79 +10 +0.9%
Wells Fargo
28
Wells Fargo
California
$16K +$8.46K +1,066 +1,938%
CUAMC
29
China Universal Asset Management Company
China
$4K +$1.96K +247 New
UBS Group
30
UBS Group
Switzerland
$2K -$10.3K -1,296 -93%
Bank of America
31
Bank of America
North Carolina
$1K -$6.77K -853 -96%
Daiwa Securities Group
32
Daiwa Securities Group
Japan
$1K – – –
SCM
33
Suvretta Capital Management
New York
– -$1.08M -200,000 Closed
Renaissance Technologies
34
Renaissance Technologies
New York
– -$138K -25,537 Closed
Two Sigma Investments
35
Two Sigma Investments
New York
– -$93K -17,138 Closed
CSS
36
Cubist Systematic Strategies
Connecticut
– -$91K -16,893 Closed
Two Sigma Advisers
37
Two Sigma Advisers
New York
– -$60K -11,100 Closed
OQS
38
Occudo Quantitative Strategies
Florida
– -$57K -10,498 Closed
Legal & General Group
39
Legal & General Group
United Kingdom
– -$9K -1,591 Closed
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
– -$1K -165 Closed
1
2

IMRX Hedge Fund Activity: Q3 2022 in Review

32 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2022, worth a combined $172M — up 162% from $65.7M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of IMRX and 5 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was Geode Capital Management, adding an estimated $754K. The largest seller was T. Rowe Price Associates, cutting an estimated $3.81M.

  • 32 institutional investors held Immuneering (IMRX) as of Q3 2022, down from 37 in Q2 2022.
  • Funds reported $172M of Immuneering stock for Q3 2022, up 162% quarter-over-quarter.
  • 5 funds opened new Immuneering positions in Q3 2022 and 10 closed out, a net change of -5 holders.
  • The largest Immuneering buyer in Q3 2022 was Geode Capital Management, an estimated $754K added.
  • The largest Immuneering seller in Q3 2022 was T. Rowe Price Associates, an estimated $3.81M sold.

Based on aggregated 13F filings for Q3 2022.